^
Association details:
| Biomarker: | CD123 expression |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | ACLX-002 (CD123-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ACLX-002, a novel CD123-targeted universal CAR-T cell therapy for relapsed or refractory acute myeloid leukemia that can be activated and silenced in vivo with soluble protein adapters in a dose dependent manner
Published date:
03/09/2022
Excerpt:
ACLX-002 also demonstrated dose- and schedule-dependent in vivo efficacy in both the MOLM14 and MV4-11 disseminated CD123-expressing tumor models in NSG immunocompromised mice, as well as multiple AML patient derived xenograft models.
